Corvus Pharmaceuticals (NASDAQ:CRVS) Given a $11.00 Price Target by Mizuho Analysts

Corvus Pharmaceuticals (NASDAQ:CRVS) received a $11.00 price objective from equities research analysts at Mizuho in a report issued on Tuesday, MarketBeat reports. The firm currently has an “outperform” rating on the stock. Mizuho’s target price suggests a potential upside of 217.00% from the company’s previous close.

Several other equities analysts have also weighed in on CRVS. HC Wainwright reissued a “buy” rating and issued a $11.00 target price on shares of Corvus Pharmaceuticals in a research note on Wednesday, March 26th. Oppenheimer reaffirmed an “outperform” rating and set a $17.00 price target (up previously from $15.00) on shares of Corvus Pharmaceuticals in a research report on Friday, May 9th. Finally, Wall Street Zen raised Corvus Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Monday, May 12th. One investment analyst has rated the stock with a sell rating and four have issued a buy rating to the stock. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average target price of $15.00.

Corvus Pharmaceuticals Trading Down 4.4%

Corvus Pharmaceuticals stock opened at $3.47 on Tuesday. Corvus Pharmaceuticals has a 1 year low of $1.75 and a 1 year high of $10.00. The company has a market cap of $236.55 million, a PE ratio of -3.73 and a beta of 0.67. The company’s 50-day moving average is $3.48 and its two-hundred day moving average is $5.19.

Corvus Pharmaceuticals (NASDAQ:CRVS) last released its earnings results on Thursday, May 8th. The company reported ($0.13) earnings per share for the quarter, meeting the consensus estimate of ($0.13). Research analysts forecast that Corvus Pharmaceuticals will post -0.63 EPS for the current year.

Institutional Inflows and Outflows

Hedge funds have recently modified their holdings of the company. Barclays PLC grew its holdings in shares of Corvus Pharmaceuticals by 10,601,800.0% during the fourth quarter. Barclays PLC now owns 106,019 shares of the company’s stock worth $567,000 after buying an additional 106,018 shares in the last quarter. JPMorgan Chase & Co. grew its holdings in shares of Corvus Pharmaceuticals by 441.5% during the third quarter. JPMorgan Chase & Co. now owns 49,556 shares of the company’s stock worth $262,000 after buying an additional 40,404 shares in the last quarter. PKS Advisory Services LLC bought a new position in shares of Corvus Pharmaceuticals during the fourth quarter worth about $56,000. Raymond James Financial Inc. bought a new position in shares of Corvus Pharmaceuticals during the fourth quarter worth about $583,000. Finally, Dimensional Fund Advisors LP grew its holdings in shares of Corvus Pharmaceuticals by 91.2% during the fourth quarter. Dimensional Fund Advisors LP now owns 22,793 shares of the company’s stock worth $122,000 after buying an additional 10,869 shares in the last quarter. 46.64% of the stock is currently owned by institutional investors.

About Corvus Pharmaceuticals

Corvus Pharmaceuticals, Inc, a clinical stage biopharmaceutical company, focuses on the development and commercialization of immune modulator product candidates to treat solid cancers, T cell lymphomas, autoimmune, allergic, and infectious diseases. Its lead product candidate is soquelitinib (CPI-818), a selective covalent inhibitor of interleukin 2 inducible T cell kinase (ITK), which is in a multi-center Phase 1/1b clinical trial for the treatment of peripheral T cell lymphoma, solid tumors, and atopic dermatitis.